Liver Cancer Drug Pipeline Analysis Report 2025
Description
Liver cancer is sometimes referred to as hepatic cancer or primary hepatic malignancy. It is the sixth most common type of cancer worldwide. Moreover, it is the fourth main cause of cancer-related deaths. 75% of primary liver malignancies are hepatocellular carcinomas (HCCs), making them the most prevalent kind. Liver cancer manifests as fever, weight loss, jaundice, and abdominal pain. Aflatoxin exposure, cirrhosis from alcohol, and hepatitis B and C infections are risk factors. Among the available treatment options include liver transplantation, radiation therapy, targeted therapy, and surgery. Moreover, the rising prevalence of the condition is anticipated to positively impact the pipeline landscape for liver cancer drugs.
Report Coverage
The Liver Cancer Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into liver cancer therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for liver cancer. The liver cancer report assessment includes the analysis of over 25 pipeline drugs and 10+ companies. The liver cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with liver cancer treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to liver cancer.
Liver Cancer Drug Pipeline Outlook
Hepatocellular carcinoma (HCC) is the most common type of liver cancer and has a complicated and multiple pathogenesis. One important stage in the viral carcinogenesis of HCC4 is cirrhosis. Chronic alcohol use, aflatoxin-B1-contaminated diet, and persistent hepatitis B (HBV) and C (HCV) viral infections have all been connected to the development of HCC. HBV can affect the development of liver cancer by increasing the expression of activating transcription factor 7 (ATF7), which promotes cell proliferation and inhibits apoptosis. Additionally, viral proteins can control cellular signaling pathways. HBV-induced hepatocarcinogenesis is caused by a combination of host-viral interactions, prolonged cycles of necrosis, inflammation, and regeneration, viral integration into the host genome, and the specific activation of oncogenic pathways by different viral proteins.
Small molecules are the most popular kind for treating liver cancer because of their capacity to effectively enter cells and target important oncogenic pathways. Small molecule tyrosine kinase inhibitors, such sorafenib and lenvatinib, are used to treat hepatocellular carcinoma (HCC) and decrease tumor growth and angiogenesis. Small molecules have superior oral bioavailability and systemic dispersion compared to oligonucleotides and peptides, which makes them more useful for treating liver cancer. Nevertheless, oligonucleotide and peptide-based treatments are being investigated for potential future developments. Further, the rising focus on the development of liver cancer emerging drugs and the advances in the understanding of the molecular pathogenesis of the disease are expected to support the pipeline expansion in the coming years.
Liver Cancer Epidemiology
Globally, liver cancer ranks as the sixth most common type of cancer. There were 866,136 new cases in 2022. Asia is home to almost 75% of liver cancer cases, with China bearing more than 50% of the global burden. The country with the greatest incidence rate is Mongolia. Males typically have two to three times the incidence and fatality rates of females. The fourth most frequent cause of cancer-related fatalities worldwide is liver cancer. According to the American Cancer Society, 42,240 new cases are expected to be detected in the United States in 2025.
Liver Cancer – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of liver cancer drug candidates based on several segmentations including:
By Phase
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total clinical trials, with a substantial number of liver cancer drugs undergoing clinical development.
Liver Cancer – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under liver cancer pipeline analysis include small molecules, biologics, peptides, and immunotherapies, among others. The liver cancer report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for liver cancer.
Liver Cancer Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the liver cancer drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed liver cancer therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in liver cancer clinical trials:
Major drugs currently in the drug pipeline are as follows:
Drug: AFPᶜ³³²T
Adaptimmune's AFPᶜ³³²T is an investigational therapy for advanced hepatocellular carcinoma (HCC) and other tumors expressing alpha-fetoprotein (AFP). This approach involves modifying a patient's own T cells to express enhanced T-cell receptors (TCRs) targeting AFP, aiming to bolster the immune system's ability to attack cancer cells. In the Phase I clinical trial, AFPᶜ³³²T demonstrated an acceptable safety profile and potential anti-tumor activity, including a complete response in one patient. The trial is ongoing, with an estimated completion date in July 2025.
Drug: Nivolumab
Nivolumab, marketed as Opdivo by Bristol-Myers Squibb, is an immunotherapy drug approved for treating hepatocellular carcinoma (HCC), the most common type of liver cancer. It functions as a PD-1 immune checkpoint inhibitor, enhancing the body's immune response against cancer cells. In the CheckMate -040 trial, Nivolumab demonstrated a 14.3% overall response rate in HCC patients previously treated with sorafenib, leading to its accelerated approval by the FDA. Ongoing studies continue to assess its efficacy in various liver cancer settings.
Reasons To Buy This Report
The Liver Cancer Drug Report provides a strategic overview of the latest and future landscape of treatments for liver cancer. it provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within the liver cancer pipeline insights.
Key Questions Answered in the Liver Cancer – Pipeline Insight Report
Global Cancer Therapeutics Market
Global Clinical Trials Market
Report Coverage
The Liver Cancer Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into liver cancer therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for liver cancer. The liver cancer report assessment includes the analysis of over 25 pipeline drugs and 10+ companies. The liver cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with liver cancer treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to liver cancer.
Liver Cancer Drug Pipeline Outlook
Hepatocellular carcinoma (HCC) is the most common type of liver cancer and has a complicated and multiple pathogenesis. One important stage in the viral carcinogenesis of HCC4 is cirrhosis. Chronic alcohol use, aflatoxin-B1-contaminated diet, and persistent hepatitis B (HBV) and C (HCV) viral infections have all been connected to the development of HCC. HBV can affect the development of liver cancer by increasing the expression of activating transcription factor 7 (ATF7), which promotes cell proliferation and inhibits apoptosis. Additionally, viral proteins can control cellular signaling pathways. HBV-induced hepatocarcinogenesis is caused by a combination of host-viral interactions, prolonged cycles of necrosis, inflammation, and regeneration, viral integration into the host genome, and the specific activation of oncogenic pathways by different viral proteins.
Small molecules are the most popular kind for treating liver cancer because of their capacity to effectively enter cells and target important oncogenic pathways. Small molecule tyrosine kinase inhibitors, such sorafenib and lenvatinib, are used to treat hepatocellular carcinoma (HCC) and decrease tumor growth and angiogenesis. Small molecules have superior oral bioavailability and systemic dispersion compared to oligonucleotides and peptides, which makes them more useful for treating liver cancer. Nevertheless, oligonucleotide and peptide-based treatments are being investigated for potential future developments. Further, the rising focus on the development of liver cancer emerging drugs and the advances in the understanding of the molecular pathogenesis of the disease are expected to support the pipeline expansion in the coming years.
Liver Cancer Epidemiology
Globally, liver cancer ranks as the sixth most common type of cancer. There were 866,136 new cases in 2022. Asia is home to almost 75% of liver cancer cases, with China bearing more than 50% of the global burden. The country with the greatest incidence rate is Mongolia. Males typically have two to three times the incidence and fatality rates of females. The fourth most frequent cause of cancer-related fatalities worldwide is liver cancer. According to the American Cancer Society, 42,240 new cases are expected to be detected in the United States in 2025.
Liver Cancer – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of liver cancer drug candidates based on several segmentations including:
By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
- Oligonucleotide
- Peptide
- Small Molecule
- Others
- Oral
- Parenteral
- Others
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total clinical trials, with a substantial number of liver cancer drugs undergoing clinical development.
Liver Cancer – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under liver cancer pipeline analysis include small molecules, biologics, peptides, and immunotherapies, among others. The liver cancer report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for liver cancer.
Liver Cancer Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the liver cancer drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed liver cancer therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in liver cancer clinical trials:
- Bristol-Myers Squibb
- Adaptimmune
- Merck Sharp & Dohme LLC
- HistoSonics, Inc.
- Mina Alpha Limited
- TriSalus Life Sciences, Inc.
- Crinetics Pharmaceuticals Inc.
- Medivir
- Camurus AB
- Celldex Therapeutics
Major drugs currently in the drug pipeline are as follows:
Drug: AFPᶜ³³²T
Adaptimmune's AFPᶜ³³²T is an investigational therapy for advanced hepatocellular carcinoma (HCC) and other tumors expressing alpha-fetoprotein (AFP). This approach involves modifying a patient's own T cells to express enhanced T-cell receptors (TCRs) targeting AFP, aiming to bolster the immune system's ability to attack cancer cells. In the Phase I clinical trial, AFPᶜ³³²T demonstrated an acceptable safety profile and potential anti-tumor activity, including a complete response in one patient. The trial is ongoing, with an estimated completion date in July 2025.
Drug: Nivolumab
Nivolumab, marketed as Opdivo by Bristol-Myers Squibb, is an immunotherapy drug approved for treating hepatocellular carcinoma (HCC), the most common type of liver cancer. It functions as a PD-1 immune checkpoint inhibitor, enhancing the body's immune response against cancer cells. In the CheckMate -040 trial, Nivolumab demonstrated a 14.3% overall response rate in HCC patients previously treated with sorafenib, leading to its accelerated approval by the FDA. Ongoing studies continue to assess its efficacy in various liver cancer settings.
Reasons To Buy This Report
The Liver Cancer Drug Report provides a strategic overview of the latest and future landscape of treatments for liver cancer. it provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within the liver cancer pipeline insights.
Key Questions Answered in the Liver Cancer – Pipeline Insight Report
- What is the current landscape of liver cancer pipeline drugs?
- Which companies/institutions are developing liver cancer emerging drugs?
- How many phase II drugs are currently present in liver cancer pipeline drugs?
- Which company is leading the liver cancer pipeline development activities?
- What is the current liver cancer therapeutic assessment?
- What are the opportunities and challenges present in the Liver Cancer drug pipeline landscape?
- What is the efficacy and safety profile of liver cancer pipeline drugs?
- Which companies/institutions are involved in liver cancer collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in liver cancer?
Global Cancer Therapeutics Market
Global Clinical Trials Market
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology & Assumptions
- 2 Executive Summary
- 3 Overview of Liver Cancer
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Types of Liver Cancer
- 3.5 Diagnosis
- 3.6 Treatment
- 4 Patient Profile: Liver Cancer
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Liver Cancer: Epidemiology Snapshot
- 5.1 Liver Cancer Incidence by Key Markets
- 5.2 Liver Cancer – Patients Seeking Treatment in Key Markets
- 6 Liver Cancer: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Liver Cancer: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Liver Cancer, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Liver Cancer Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Liver Cancer Drug Pipeline - Mid-Stage Products (Phase III & IV) (Top Drugs)
- 10.1 Comparative Analysis for Mid-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Drug: CAM2029
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Drug: RC48-ADC
- 10.2.3 Other Drugs
- 11 Liver Cancer Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Drug: Nivolumab
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Drug: Zanubrutinib
- 11.2.3 Other Drugs
- 12 Liver Cancer Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Drug: AFP?³³²T
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Drug: SD-101
- 12.2.3 Other Drugs
- 13 Liver Cancer, Key Drug Pipeline Companies
- 13.1 Bristol-Myers Squibb
- 13.1.1 Company Snapshot
- 13.1.2 Pipeline Product Portfolio
- 13.1.3 Financial Analysis
- 13.1.4 Recent News and Developments
- 13.2 Adaptimmune
- 13.2.1 Company Snapshot
- 13.2.2 Pipeline Product Portfolio
- 13.2.3 Financial Analysis
- 13.2.4 Recent News and Developments
- 13.3 Merck Sharp & Dohme LLC
- 13.3.1 Company Snapshot
- 13.3.2 Pipeline Product Portfolio
- 13.3.3 Financial Analysis
- 13.3.4 Recent News and Developments
- 13.4 HistoSonics, Inc.
- 13.4.1 Company Snapshot
- 13.4.2 Pipeline Product Portfolio
- 13.4.3 Financial Analysis
- 13.4.4 Recent News and Developments
- 13.5 Mina Alpha Limited
- 13.5.1 Company Snapshot
- 13.5.2 Pipeline Product Portfolio
- 13.5.3 Financial Analysis
- 13.5.4 Recent News and Developments
- 13.6 Adicet Therapeutics
- 13.6.1 Company Snapshot
- 13.6.2 Pipeline Product Portfolio
- 13.6.3 Financial Analysis
- 13.6.4 Recent News and Developments
- 13.7 TriSalus Life Sciences, Inc.
- 13.7.1 Company Snapshot
- 13.7.2 Pipeline Product Portfolio
- 13.7.3 Financial Analysis
- 13.7.4 Recent News and Developments
- 13.8 Crinetics Pharmaceuticals Inc.
- 13.8.1 Company Snapshot
- 13.8.2 Pipeline Product Portfolio
- 13.8.3 Financial Analysis
- 13.8.4 Recent News and Developments
- 13.9 Medivir
- 13.9.1 Company Snapshot
- 13.9.2 Pipeline Product Portfolio
- 13.9.3 Financial Analysis
- 13.9.4 Recent News and Developments
- 13.10 Camurus AB
- 13.10.1 Company Snapshot
- 13.10.2 Pipeline Product Portfolio
- 13.10.3 Financial Analysis
- 13.10.4 Recent News and Developments
- 13.11 Celldex Therapeutics
- 13.11.1 Company Snapshot
- 13.11.2 Pipeline Product Portfolio
- 13.11.3 Financial Analysis
- 13.11.4 Recent News and Developments
- 14 Regulatory Framework for Drug Approval, By Region
- 15 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
